Publication date: Aug 01, 2023
Galectin (Gal)-3 is a β-galactoside-binding lectin emerging as a key player in cardiac, hepatic, renal, and pulmonary fibrosis and inflammation, respiratory infections caused by COVID-19, and neuroinflammatory disorders. Here, we review recent information highlighting Gal-3 as a relevant therapeutic target in these specific disease conditions. While a causal link was difficult to establish until now, we discuss how recent strategic breakthroughs allowed us to identify new-generation Gal-3 inhibitors with improved potency, selectivity, and bioavailability, and report their usefulness as valuable tools for proof-of-concept studies in various preclinical models of the aforementioned diseases, with emphasis on those actually in clinical stages. We also address critical views and suggestions intended to expand the therapeutic opportunities provided by this complex target.
| Concepts | Keywords |
|---|---|
| Bioavailability | drug |
| Gal | fibrosis |
| Hepatic | galectin-3 |
| Inhibitors | inflammation |
| New | target |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | pulmonary fibrosis |
| disease | MESH | inflammation |
| disease | MESH | respiratory infections |
| disease | MESH | COVID-19 |
| disease | MESH | neuroinflammatory disorders |
| disease | VO | report |
| disease | MESH | fibrosis |